RxDoctor Payments Data

James Young, MD

Urology · Virginia Beach, VANPI 1619956661

Payments from drug & device makers

$7,748in general payments, 2019–2025

Across 153 payments — averaging $50.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arrow International, Inc.$2K
  • Teleflex LLC$2K
  • KARL Storz Endoscopy-america$1K
  • Procept Biorobotics Corporation$522
  • Johnson & Johnson$464
  • Astellas Pharma US Inc$295
  • plus $2K from 25 others

What the payments were for

  • Grants$1252%
  • Travel & lodging$2,59244%
  • Food & beverage$3,11553%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,748 in reported general payments places this provider in the 65th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$562,655
Medicare patients
1,565
Services billed
7,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron63$60,155
Potassium Citrate ErPotassium Citrate38$5,292
Tamsulosin Hcl351$5,269
Finasteride217$2,903
Silodosin26$2,721
Tolterodine Tartrate ErTolterodine Tartrate35$2,537
Testosterone Cypionate35$1,926
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst70$1,113
Solifenacin Succinate17$1,023
Alfuzosin Hcl ErAlfuzosin Hcl49$951
Dutasteride30$888
Linezolid14$838
Trospium Chloride14$711
NitrofurantoinNitrofurantoin Macrocrystal23$486
Cefdinir26$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$295$60,15563 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 300 urology providers in Virginia.

Other urology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →